Elizabeth Holmes promised a machine that could run hundreds of blood tests from a single finger-prick. The Edison device sat at the center of a $9 billion company β and it barely worked. This is the postmortem on Theranos: what the team expected, what the science actually showed, where the decision-making crossed the line, and what the health-tech industry has quietly changed because of it.